Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 674, Issue 1-2, 2009, Pages 93-100

  Martin, Nicholas J ^a   Collier, Abby C ^a,d   Bowen, Lance D ^a   Pritsos, Karen L ^a   Goodrich, Geoffrey G ^a   Arger, Kosta ^c   Cutter, Gary ^b   Pritsos, Chris A ^a  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Sierra Nevada Cardiology Associates   (United States)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

Coronary heart disease; Genetic polymorphisms; Glutathione S transferase; NQO1; Oxidative stress; Smoking

Indexed keywords

ANTIOXIDANT; C REACTIVE PROTEIN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENOTYPE; HETEROZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX RATIO; SMOKING;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; MUTATION, MISSENSE; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATIVE STRESS; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 61649109975     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2008.09.009     Document Type: Article

References (37)

1. Fried V., Prager K., Mackay A., and Xia H. Health United States 2003 (2003), National Center for Health Statistics, Hyattsville
2. N.C.f.H. Statistics National Health Interview Survey 2000, Centers for Disease Control and Prevention, Hyattsville, 2000, p. 92.
3. Lusis A. Atherosclerosis. Nature 407 (2000) 233-241
4. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine (1997), WB Saunders and Company, Philadelphia
5. Eagles C., and Martin U. Non-pharmacological modification of cardiac risk factors: Part 3. Smoking cessation and alcohol consumption. J. Clin. Pharmacol. Ther. 23 (1998) 1-9
6. Khot U., Khot M., Bajzer C., Sapp S., Ohman E., Brener S., Ellis S., Lincoff A., and Topol E. Prevalence of conventional risk factors in patients with coronary heart disease. J. Am. Med. Assoc. 290 (2003) 898-904
7. Steinberg D., Parthasarathy S., Carew T., Khoo J., and Witztum J. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320 (1989) 915-924
8. Pasricha A., and Batchelor W. When young hearts are broken: profiles of premature myocardial infarction. Am. Heart J. 143 (2002) 4-6
9. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
10. Waart F.d., Kok F., Smilde T., Hijmans A., Wollersheim H., and Stalenhoef A. Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers. Atherosclerosis 158 (2001) 227-231
11. Li R., Boerwinkle E., Olshan A.F., Chambless L.E., Pankow J.S., Tyroler H.A., Bray M., Pittman G.S., Bell D.A., and Heiss G. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis 149 (2000) 451-462
12. Miller E.A., Pankow J.S., Millikan R.C., Bray M.S., Ballantyne C.M., Bell D.A., Heiss G., and Li R. Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 171 (2003) 265-272
13. Clairmont A., Sies H., Ramachandran S., Lear J.T., Smith A.G., Bowers B., Jones P.W., Fryer A.A., and Strange R.C. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 20 (1999) 1235-1240
14. Park S., Zhao H., Spitz M., Grossman H., and Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mut. Res. 536 (2003) 131-137
15. Sachse C., Smith G., Wilkie M.J.V., Barrett J.H., Waxman R., Sullivan F., Forman D., Bishop D.T., and Wolf C.R. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23 (2002) 1839-1850
16. Siegelmann-Danieli N., and Buetow K.H. Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology 62 (2002) 39-45
17. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., and Siegel D. NAD(P)H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chemico-Biol. Interact. 129 (2000) 77-97
18. Gilfix B., Blank D., and Rosenblatt D. Novel reductant for determination of total plasma homocysteine. Clin. Chem. 43 (1997) 687-688
19. Kim W., Lee H., Lee S., Kim Y., and Kim H. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J. Urol. 164 (2000) 209-213
20. Chen H., Lum A., Seifried A., Wilkens L., and Marchand L.L. Association of the NAD(P)H:quinone oxidoreductase 609C → T polymorphism with a decreased lung cancer risk. Cancer Res. 59 (1999) 3045-30448
21. Pepys M., and Hirschfield G. C-reactive protein: a critical update. J. Clin. Invest. 111 (2003) 1805-1812
22. Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 358 (2008) 2148-2159
23. Rasouli M.L., Khurram N., Roger S.B., Robert P., Douglas C.A., and Matthew J.B. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis 181 (2005) 159-165
24. Surekha R.H., Srikanth B.B., Jharna P., Ramachandra R.V., Dayasagar R.V., and Jyothy A. Oxidative stress and total antioxidant status in myocardial infarction. Singapore Med. J. 48 (2007) 137-142
25. Li R., Boerwinkle E., Olshan A., Chambless L., Pankow J., Tyroler H., Bray M., Pittman G., Bell D., Douglas A., and Heiss G. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis 149 (2000) 451-462
26. Parsricha A., and Batchelor W. When young hearts are broken: profiles of premature myocardial infarction. Am. Heart J. 143 (2002) 4-6
27. Masetti S., Botto N., Manfredi S., Colombo M., Rizza A., Vassalle C., Clerico A., Biagini A., and Andreassi M. Interactive effect of the glutathione S-transferase genes and cigarette smoking on occurrence and severity of coronary artery risk. J. Mol. Med. 81 (2003) 488-494
28. Hong C.-C., Ambrosone C.B., Ahn J., Choi J.-Y., McCullough M.L., Stevens V.L., Rodriguez C., Thun M.J., and Calle E.E. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1784-1794
29. Tijhuis M.J., Visker M.H., Aarts J.M., Laan W., deBoer S.Y., Kok F.J., and Kampman E. NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population. Int. J. Cancer 122 (2008) 1842-1848
30. Steiner M., Hillenbrand M., Borkowsi M., Seiter H., and Schuff-Werner P. 606C → T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett. 135 (1998) 67-71
31. Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 36 (2004) 639-654
32. William L.A.H.B.M., and Baird M. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ. Mol. Mutagen. 45 (2005) 106-114
33. Beall H.D., Liu Y., Siegel D., Bolton E.M., Gibson N.W., and Ross D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem. Pharmacol. 51 (1996) 645-652
34. Gibson N.W., Hartley J.A., Butler J., Siegel D., and Ross D. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol. Pharmacol. 42 (1992) 531-536
35. Nygard O., Nordrehaug J., Refsum H., Ueland P., Farstad M., and Volleset S. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337 (1997) 230-236
36. Ridker P., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344 (2001) 1959-1965
37. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., Lowe G.D., Pepys M.B., and Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1397